

Guideline Page and Request	Panel Discussion/References	Institution Vote			
		YES	NO	ABSTAIN	ABSENT
NET-10 External request: Submission from Lexicon Pharmaceuticals, Inc. to consider the inclusion of telotristat ethyl, based on category 1 evidence, for the treatment of carcinoid syndrome (CS) in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. Recommending 250 mg po tid as initial therapy, and with consideration that 500 mg po tid may be beneficial in patients not adequately responding to initial therapy with 250 mg tid.	Based on the data in the noted reference, the panel consensus was to include telotristat ethyl, in combination with octreotide or lanreotide, as a category 2A recommended option for the treatment of persistent diarrhea from poorly controlled carcinoid syndrome, for patients with gastrointestinal tract, lung, or thymus neuroendocrine tumors. The recommended dosing that has been included for telotristat is 250 mg orally, three times daily. References: <ul style="list-style-type: none"> Kulke MH, Hörsch D, Caplin ME, et al. Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome. J Clin Oncol. 2017;35(1):14-23. See Submission for additional references 	18	0	2	7